<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835481</url>
  </required_header>
  <id_info>
    <org_study_id>1407-0005</org_study_id>
    <secondary_id>2018-003487-31</secondary_id>
    <nct_id>NCT03835481</nct_id>
  </id_info>
  <brief_title>A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is</brief_title>
  <official_title>Phase II Long-term Extension Study to Assess the Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate&#xD;
      to severe chronic plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">June 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to Week 288</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Psoriasis Area and Severity Index (PASI)50/PASI75/PASI90/PASI100</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Static Physician's Global Assessment (sPGA) score 0 (clear) or 1 (almost clear)</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of sPGA score 0 (clear)</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of PASI50/PASI75/PASI90/PASI100 for patients who achieve the response</measure>
    <time_frame>Up to Week 288</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of sPGA clear or almost clear for patients who achieve the response</measure>
    <time_frame>Up to Week 288</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of sPGA clear for patients who achieve the response</measure>
    <time_frame>Up to Week 288</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded period of Placebo until Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 730357 Fasted Condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded period of BI 730357 until Week 12 (4 dose levels or placebo as continued from trial 1407-0030). Open label period of BI30357 from Week 12 to end of trial (2 dose levels).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 730357 Fed Condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients entering extension trial from Part 2 of trial 1407-0030</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 730357</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>BI 730357 Fasted Condition</arm_group_label>
    <arm_group_label>BI 730357 Fed Condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match BI 730357</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman Of Child Bearing Potential (WOCBP) must be ready and able to use highly&#xD;
             effective methods of birth control per International Conference on Harmonisation (ICH)&#xD;
             M3 (R2) that result in a low failure rate of less than 1% per year when used&#xD;
             consistently and correctly from date of screening until 4 weeks after last treatment&#xD;
             in this trial. A list of contraception methods meeting these criteria is provided in&#xD;
             the patient information.&#xD;
&#xD;
          -  Patients with moderate-to-severe plaque Psoriasis (PsO) who have completed treatment&#xD;
             in the preceding trial without early discontinuation, agree to continue treatment in&#xD;
             1407-0005, and&#xD;
&#xD;
               -  for patients entering from Part 1 of trial 1407-0030&#xD;
&#xD;
                  --- achieve a ≥PASI50 response upon completing the trial 1407-0030 Week 24&#xD;
                  end-of-treatment visit&#xD;
&#xD;
               -  for patients entering from Part 2 of trial 1407-0030 --- achieve a ≥PASI50&#xD;
                  response upon completing the trial 1407-0030 Week 12 end-of-treatment visit or&#xD;
                  perceived patient improvement, at the discretion of the Investigator&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nonplaque forms of PsO (including guttate, erythrodermic, or pustular), current&#xD;
             druginduced PsO (including a new onset or exacerbation of PsO from, e.g., beta&#xD;
             blockers, calcium channel blockers, lithium), active ongoing inflammatory diseases&#xD;
             (including but not limited to inflammatory bowel disease (IBD)) other than PsO that&#xD;
             might confound trial evaluations.&#xD;
&#xD;
          -  Previous enrolment in this trial.&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug trial or is receiving&#xD;
             other investigational treatment(s) (with the exception of 1407-0030).&#xD;
&#xD;
          -  Intake of any restricted medication or any drug considered likely to interfere with&#xD;
             the safe conduct of the trial.&#xD;
&#xD;
          -  Any plan to receive a live vaccination during the conduct of the trial.&#xD;
&#xD;
          -  Patients not expected to comply with the protocol requirements or not expected to&#xD;
             complete the trial as scheduled.&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes the patient an unreliable trial participant or unlikely to complete the trial.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.&#xD;
&#xD;
          -  Any documented active or suspected malignancy, except appropriately treated basal cell&#xD;
             carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of&#xD;
             uterine cervix.&#xD;
&#xD;
          -  Relevant chronic or acute infections including human immunodeficiency virus (HIV),&#xD;
             viral hepatitis and tuberculosis.&#xD;
&#xD;
          -  Evidence of a disease (including known or suspected IBD, cardiovascular disease), or&#xD;
             medical finding that in the opinion of the Investigator is clinically significant and&#xD;
             would make the study participant unreliable to adhere to the protocol or to complete&#xD;
             the trial, compromise the safety of the patient, or compromise the quality of the&#xD;
             data.&#xD;
&#xD;
          -  Any suicidal ideation, including grade 4 or 5 in the Columbia Suicide Severity Rating&#xD;
             Scale (C-SSRS) in the past 12 months (i.e., active suicidal thought with intent but&#xD;
             without specific plan), or active suicidal thought with plan and intent in the past.&#xD;
&#xD;
          -  Unwillingness to adhere to the rules of UV-light protection&#xD;
&#xD;
          -  Ongoing AEs consistent with intolerance of trial medication (including gastric&#xD;
             intolerance) from 1407-0030, that in the opinion of the investigator would compromise&#xD;
             the safety of the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Research</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Chih-ho Hong Medical Inc</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Irina Turchin PC Inc.</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Clinical Trials</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TFS Trial Form Support GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

